Ozempic vs Wegovy. Same molecule, different product.

Quick comparison at a glance

The short version — here is how Ozempic and Wegovy stack up on the questions most patients ask before picking one.

Ozempic

• Drug class: GLP-1 receptor agonist
• Brand names: Ozempic (semaglutide 0.25, 0.5, 1.0, 2.0 mg)
• Mechanism: Same as Wegovy — semaglutide mimics the gut hormone GLP-1 to regulate blood sugar, slow gastric emptying, and reduce appetite.
• Dosing: Once-weekly subcutaneous injection. Doses of 0.25, 0.5, 1.0, or 2.0 mg. Titrated up over time.
• Half-life: Approximately 7 days.
• FDA indication: Adults with type 2 diabetes to improve glycemic control. Also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
• FDA status: FDA-approved in 2017. Widely used and insurance-covered for diabetes.
• Manufacturer: Novo Nordisk
• Common side effects: Nausea, vomiting, diarrhea, constipation, decreased appetite — standard semaglutide profile.
• Typical price range: Brand price is roughly $900-1,100/month without insurance. Typically covered for type 2 diabetes with prior authorization.

Wegovy

• Drug class: GLP-1 receptor agonist
• Brand names: Wegovy (semaglutide 0.25-2.4 mg)
• Mechanism: Same as Ozempic — semaglutide. Wegovy is specifically packaged, dosed, and labeled for weight management.
• Dosing: Once-weekly subcutaneous injection. Titrated from 0.25 mg to 2.4 mg (higher max than Ozempic) over about 16 weeks.
• Half-life: Approximately 7 days.
• FDA indication: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Also FDA-approved for cardiovascular risk reduction in a subset of patients.
• FDA status: FDA-approved in 2021 based on the STEP clinical trial program.
• Manufacturer: Novo Nordisk
• Common side effects: Same side effect profile as Ozempic since they are the same molecule. At the 2.4 mg weight-management dose, some patients report slightly higher GI side effects than at Ozempic's lower diabetes doses.
• Typical price range: Roughly $1,300+/month brand price without insurance. Coverage for weight management varies widely by plan.

Yes, they are the same drug

Ozempic and Wegovy contain identical active ingredient: semaglutide. Both are manufactured by Novo Nordisk. Both are delivered as once-weekly subcutaneous injections. If you look at the pharmacology, they are the same molecule doing the same thing to the same receptors.

The differences come from packaging, labeling, and FDA-approved indications. Ozempic was developed first as a type 2 diabetes drug. Wegovy was developed second with a higher maximum dose (2.4 mg vs Ozempic's 2.0 mg) and with specific clinical trial data supporting weight management — the STEP trial program. The FDA reviewed each as a separate product and approved them for different indications.

Why the distinction matters in practice

If they are the same drug, why can't you just use Ozempic for weight loss? Several reasons, all practical rather than pharmacologic.

• Insurance coverage. Ozempic is typically covered by insurance for type 2 diabetes under prior authorization requirements. Using Ozempic off-label for weight loss in a patient without diabetes means the insurance claim may be denied — and many payers have tightened this explicitly.
• Dosing range. Wegovy tops out at 2.4 mg weekly; Ozempic tops out at 2.0 mg. That additional 0.4 mg is the dose shown in STEP 1 to produce average weight loss of about 14.9%. Some patients do well at Ozempic's maximum; others need the Wegovy maximum.
• Supply. During periods of semaglutide shortage, Ozempic and Wegovy have been prioritized differently by Novo Nordisk. A patient may find Ozempic available when Wegovy is back-ordered, or vice versa.
• Physician documentation. Prescribing Ozempic off-label for weight loss in a non-diabetic patient creates specific documentation requirements and ethical considerations. Most responsible prescribers write Wegovy for the FDA-approved indication whenever they can.

What off-label prescribing actually means

Off-label prescribing is legal and common in US medicine. Physicians can prescribe an FDA-approved drug for a use other than its FDA-approved indication when they believe it is clinically appropriate. This happens constantly — beta blockers for migraine, certain antidepressants for chronic pain, many others.

Prescribing Ozempic off-label for weight management in a non-diabetic patient was common when Wegovy was in short supply or unavailable. Many physicians did it in good faith, with the goal of providing access to a medication that had strong clinical evidence for weight loss. Insurance often refused to cover it, but it was not illegal.

Today, with Wegovy more widely available, the appropriate choice for a patient whose primary goal is weight management is usually Wegovy or an alternative path like compounded semaglutide, not off-label Ozempic. A physician will make that call based on your specific situation.

Who tends to do better on each

There is no universally better option — only a better fit for your specific clinical picture, history, budget, and preferences. A licensed physician reviews all of those before prescribing. Here is the honest framing on who typically does better on each.

Ozempic

Ozempic is the right choice for adults with type 2 diabetes who are candidates for semaglutide to manage blood sugar (and who may also benefit from weight loss as a secondary effect). It is not FDA-approved for weight loss in patients without type 2 diabetes, though it is sometimes prescribed off-label for that purpose.

Wegovy

Wegovy is the right choice for adults with obesity or overweight plus a weight-related condition who want the FDA-approved weight-management dosing and labeling, and whose insurance may cover the weight-management indication (or who can pay the cash price). It is the appropriate prescription for a patient whose primary goal is weight management, not diabetes treatment.